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Abstract
PKC-y is important in cell growth, apoptosis, and secretion. Recent studies show its stability is regulated by tyrosine phosphorylation
(TYR-P), which can be stimulated by a number of agents. Many of these stimuli also activate phospholipase C (PLC) cascades and little is
known about the relationship between these cascades and PKC-y TYR-P. Cholecystokinin (CCK) stimulates PKCs but it is unknown if it
causes PKC-y TYR-P and if so, the relationship between these cascades is unknown. In rat pancreatic acini, CCK-8 stimulated rapid PKC-y
TYR-P by activation of the low affinity CCKA receptor state. TPA had a similar effect. BAPTA did not decrease CCK-stimulated PKC-y TYR-
P but instead, increased it. A23187 did not stimulate PKC-y TYR-P. Wortmannin and LY 294002 did not alter CCK-stimulated PKC-y TYR-P.
GF 109203X, at low concentrations, increased PKC-y TYR-P stimulated by CCK or TPA and at higher concentrations, inhibited it. The cPKC
inhibitors, Go¨ 6976 and safingol, caused a similar increase in TPA- and CCK-stimulated PKC-y TYR-P. These results demonstrate that CCKA
receptor activation causes PKC-y TYR-P through activation of only one of its two receptor affinity states. This PKC-y TYR-P is not directly
influenced by changes in [Ca2 +]i; however, the resultant activation of PKC-a has an inhibitory effect. Therefore, CCK activates both
stimulatory and inhibitory PKC cascades regulating PKC-y TYR-P and, hence, likely plays an important role in regulating PKC-y degradation
and cellular abundance.
Published by Elsevier Science B.V.
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1. Introduction
The peptide, cholecystokinin (CCK), functions as both a
neurotransmitter (in the central nervous system and gastro-
intestinal tract) as well as a hormone in the gastrointestinal
tract with numerous biologic effects [1]. In the central
nervous system CCK is one of the abundant neuropeptides
and is involved in such diverse actions as modulating
dopamine release, satiety, morphine-induced analgesia, and
the induction of panic attacks [2]. In the gastrointestinal tract,
CCK is a physiological regulator of postprandial pancreatic
secretion, gallbladder contraction, gastric emptying, and
colonic motility [1,3].
The actions of CCK-related peptides (CCK, gastrin) are
mediated by two different subtypes of CCK receptors which
are members of the G protein-coupled heptahelical super-
family [3,4]: a CCKA receptor with high affinity for sulfated
CCK peptides only, and a CCKB receptor with high affinity
for both sulfated CCK and gastrin analogues [3]. The cellular
basis of action of CCK at the CCKA-R, which is widely
expressed in the gastrointestinal tract and central nervous
system, has been extensively studied in pancreatic acinar
cells where CCK stimulates enzyme secretion [1,4,5], growth
[6], development [7], protein synthesis [1,5], and regulation
of c-fos, c-Jun and c-myc expression [8]. Extensive studies
show that CCK causes activation of phospholipase A2,
phospholipase D, and phospholipase C (PLC) [5]. The
activation of PLC results in generation of diacylglycerol
and increased inositol 1,4,5-trisphosphate with subsequent
activation of protein kinase C (PKC), stimulation of increases
in intracellular calcium concentration, and activation of mi-
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togen-activated protein kinase (MAPK) signaling pathways
[5]. Recent studies have demonstrated that CCKA receptor
activation [9–11], similar to the activation in different tissues
by integrins, bioactive lipids, various growth factors, and
some G protein-coupled receptors, causes stimulation of
tyrosine phosphorylation of a number of proteins [5,12,13].
With other stimulants, activation of this important intra-
cellular pathway has been shown to be particularly important
in mediating cellular growth, differentiation, motility, and
adaptation to cellular stresses [12,13].
With CCKA receptor activation, similar to other stimu-
lants which activate PLC and tyrosine kinases, the relation-
ship between activation of both of these transduction
cascades remains poorly defined, as well as their respective
roles in many cell functions such as growth and differ-
entiation. In this regard, the protein kinase C delta (PKC-y)
isoform is of particular interest, because numerous studies
demonstrate this serine–threonine kinase is not only acti-
vated by diacylglycerol from PLC and PLD activation, but
also undergoes tyrosine phosphorylation itself [14,15],
which can either increase [14,16–18] or decrease [14,
19,20] its kinase activity. Furthermore, tyrosine phosphory-
lation of PKC-y is an important means of regulating its cell
abundance, because a recent study demonstrates that PKC-y
tyrosine phosphorylation increases its instability, which
results in increased degradation [21]. PKC-y activation has
been proposed to be involved in a wide range of cellular
responses including regulation of cell growth, differentia-
tion, apoptosis, tumor suppression, secretion (fluid and
electrolyte), various ion channels [L-channels, Na-H+
exchangers (GLUT-4)], phosphoinositide hydrolysis, and
prostaglandin formation [14,16,22–24].
Four different PKC isoforms have been detected in
pancreatic acinar cells, including the conventional PKC
(cPKC), PKC-a, the novel PKC (nPKC) isoforms, PKC-y
and PKC-q, and the atypical isoform, PKC-~ [25,26].
Whereas the role of stimulation of the PLC cascade by
CCKA receptor activation resulting in stimulation of the
classical PKC isoform due to increases in cytosolic calcium
secondary to the generation of phosphoinositides and
increases in diacylglycerol generation due to the breakdown
of phospholipids, have been extensively studied [5], little is
known about the ability of CCK to activate nPKCs such as
PKC-y. No studies have examined whether CCK can stim-
ulate tyrosine phosphorylation of PKC-y or the possible
relationships between this process and activation of the
PLC cascade.
In the present study using dispersed rat pancreatic acini,
we show that CCKA receptor activation results in a rapid
tyrosine phosphorylation of PKC-y. This tyrosine phosphor-
ylation is due to activation only of the low affinity state of the
CCKA receptor, and is not dependent directly on changes in
cytosolic calcium, and our results show for the first time that
tyrosine phosphorylation of PKC-y is regulated in a positive
and negative manner by activation of conventional and novel
PKCs in the acinar cell.
2. Materials and methods
2.1. Materials
Male Wistar rats (150-200 g) were obtained from the
Small Animals Section, Veterinary Resources Branch, NIH,
Bethesda, MD or from the Animal Farm, Faculty of Veteri-
nary, UEX, Spain. Purified collagenase (type CLSPA) from
Worthington Biochemicals, Freehold, NJ; COOH-terminal
octapeptide of cholecystokinin (CCK-8) was obtained from
Peninsula Laboratories, Belmont, CA; CCK-JMV was ob-
tained from Research Plus Inc., Bayonne, NJ. Anti-phos-
photyrosine mAb (PY20), anti-p125FAK mAb, anti-paxillin
mAb, anti-PKC-a mAb, and anti-PKC-y mAb were from
Transduction Laboratories, Lexington, KY. Anti-PKC-y pol-
yclonal Ab and goat anti-rabbit IgG–horseradish peroxidase
conjugate were from Santa Cruz Biotechnology, Inc., Santa
Cruz, CA. Anti-phosphotyrosine mAb, myelin basic protein,
and recombinant protein A–agarose were from Upstate
Biotechnology Inc., Lake Placid, NY. GF 109203X, safingol,
Go¨ 6976, calcium ionophore, A23187, and thapsigargin
were from Calbiochem, La Jolla, CA. Soybean trypsin
inhibitor (SBTI), dimethyl sulfoxide (DMSO), Triton X-
100, 12-O-tetradecanoylphorbol 13-acetate (TPA), and
deoxycholic acid were from Sigma, St. Louis, MO; phenyl-
methanesulfonyl fluoride (PMSF) was from Fluka, Ronkon-
koma, NY. Phosphate-buffered saline (PBS), pH 7.4, was
from Biofluids, Rockville, MD; basal medium Eagle (BME)
amino acids and BME vitamin solution were from Gibco
Laboratories, Grand Island, NY. Bovine serum albumin
(BSA) fraction V was from Miles Inc., Kankakee, IL. Ap-
rotinin, leupeptin, and 4-[2-hydroxyethyl]-1-piperazine etha-
nesulfonic acid (HEPES) were from Boehringer Mannheim
Biochemicals, Indianapolis, IN. Rabbit anti-mouse IgG–
horseradish peroxidase conjugate and enhanced chemilu-
minescence detection reagents were from Pierce, Rockford,
IL. Sodium dodecyl sulfate (SDS), 2-mercaptoethanol, pro-
tein assay dye reagent, Tris/glycine/SDS buffer (10-times
concentrated), and Tris/glycine buffer (10 times concen-
trated) were from Bio-Rad, Richmond, CA. BAPTA acetox-
ymethyl ester (BAPTA/AM) and fura-2 acetoxymethyl ester
(fura-2/AM) were from Molecular Probes, Eugene, OR.
Hyperfilm and [g32P]ATP were from Amersham, Arlington
Heights, IL, and nitrocellulose membrane was from
Schleicher & Schuell, Keene, NH.
2.2. Methods
2.2.1. Tissue preparation
Dispersed rat pancreatic acini were prepared as described
previously [9–11]. Unless otherwise stated, the standard
incubation solution contained (in mM): HEPES (25.5) [pH
7.4]; NaCl (98); KCl (6); NaH2PO4 (2.5); sodium pyruvate
(5); sodium fumarate (5); sodium glutamate (5); glucose
(11.5); CaCl2 (0.5); MgCl2 (1); glutamine (2); albumin 1%
(w/v); trypsin inhibitor 1% (w/v); vitamin mixture, 1% (v/v)
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and amino acid mixture, 1% (w/v). The incubation solution
was equilibrated with 100% O2 and all incubations were
performed with 100% O2 as the gas phase.
2.2.2. Intracellular calcium measurement
After isolation, pancreatic acini were resuspended in
NaHEPES medium containing 130 mM NaCl, 5 mM
KCl, 20 mM HEPES, 1.2 mM KH2PO4, 10 mM D-glucose,
1 mM CaCl2, 0.1 mg/ml trypsin inhibitor, and loaded with
2 AM fura 2/AM for 30–40 min at 25 jC. Changes in
[Ca2 +]i were assessed using a spectrofluorophotometer RF-
5001PC (Shimadzu Europe GmbH, Duisburg, Denmark) as
described previously [10]. Fluorescence was measured at
500 nm after excitation at 340 nm (F340) and 380 nm
(F380). Values for [Ca
2 +]i were calculated, after subtraction
of background autofluorescence, as described previously
[10].
2.2.3. Immunoprecipitation
Immunoprecipitation of tyrosine-phosphorylated proteins
was performed as described previously [9–11]. Dispersed
acini from one rat were preincubated with standard incuba-
tion solution without or with different inhibitors, at concen-
trations and times indicated, for up to 3 h at 37 jC. Aliquots
(1 ml) were then incubated at 37 jC with different agonists at
the concentrations and times indicated. Acinar lysates were
obtained as described previously [9] using sonication in lysis
buffer [50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1% Triton
X-100, 1% deoxycholate, 0.1% (w/v) NaN3, 1 mM EGTA,
0.4 mM EDTA, 2.5 Ag/ml aprotinin, 2.5 Ag/ml leupeptin, 1
mM PMSF and 0.2 mM Na3VO4]. For tyrosine phosphor-
Fig. 1. CCK-8 and the phorbol ester TPA stimulate PKC-y tyrosine
phosphorylation in rat pancreatic acini. Rat pancreatic acini were treated
with no additions (lane 1), with 1 AMof TPA for 5min (lane 2) or with 10 nM
of CCK-8 for 2.5 min (lane 3) and then lysed. Whole lysates were
immunoprecipitated (IP) with anti-PKC-y polyclonal antibody (aPKC-y, top
and middle panels) or anti-phosphotyrosine monoclonal antibody (aPTyr,
bottom panel). Immunoprecipitates were analyzed byWestern blotting (WB)
using either aPTyr mAb (top panel) or aPKC-y polyclonal Ab (middle and
bottom panels). Positions ofmolecular weight marked are shown in the Y-axis
on the left. The position of PKC-y is indicated with the arrow on the left. The
autoradiograms are representative of three independent experiments in
duplicate.
Fig. 2. Time-course (top panel) and concentration dependence (bottom
panel) of CCK-8 stimulation of PKC-y tyrosine phosphorylation in rat
pancreatic acini. Rat pancreatic acini were treated with 10 nM of CCK-8 for
the indicated times (top panel) or for 2.5 min with the indicated
concentrations of CCK-8 (bottom panel) and then lysed. Whole-cell lysates
were immunoprecipitated with anti-PKC-y polyclonal Ab. Immunoprecipi-
tates were analyzed by SDS-PAGE followed by transfer of proteins of
molecular weight >60 kDa to nitrocellulose membrane and anti-phospho-
tyrosine immunoblotting as described in Methods. Bands were visualized
using chemiluminescence and quantification of phosphorylation was
performed by scanning densitometry. Top panel: The upper part shows
results from a representative experiment with CCK-8 (10 nM) at the
indicated times. These results are representative of three others in duplicate.
The values shown in the bottom part are meanF S.E. of four independent
experiments and are expressed as the percentage of maximal response
caused by CCK-8 (10 nM) at 2.5 min above control unstimulated values.
Bottom panel: The upper part shows results from a representative
experiment with CCK-8 at the indicated concentrations. These results are
representative of three others in duplicate. The values shown in the bottom
part are meanF S.E. of four independent experiments and are expressed as
the percentage of maximal response caused by 100 nM of CCK-8 above
unstimulated values.
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ylation determination, lysates (500 Ag/ml) were preincubated
with 4 Ag of anti-phosphotyrosine mAb (PY20) or 4 Ag anti-
PKC-y polyclonal Ab and 25 Al of protein A–agarose over-
night at 4 jC. Then the immunoprecipitates were washed
three times with phosphate-buffered saline and further ana-
lyzed by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting.
2.2.4. Western blotting
Western blotting was performed as described previously
[9–11]. Anti-phosphotyrosine or anti-PKC-y immunopreci-
pitates were fractionated by SDS-PAGE using 10% poly-
acrylamide gels. Proteins with molecular masses higher than
60 kDa were transferred to nitrocellulose membranes.
Membranes were blocked overnight at 4 jC using blotto
[5% nonfat dried milk in a solution containing 50 mM Tris/
HCl pH 8.0, 2 mM CaCl2, 80 mM NaCl, 0.05% (v/v) Tween
20] and incubated for 2 h at 25 jC with 1 Ag/ml of anti-
phosphotyrosine mAb, 0.25 Ag/ml of anti-PKC-y polyclonal
Ab, 0.25 Ag/ml of anti-p125FAK mAb or 0.025 Ag/ml anti-
paxillin mAb. After incubation with the primary antibody,
membranes were washed twice for 4 min with blotto and
incubated for 45 min at 25 jC with anti-mouse IgG–
horseradish peroxidase conjugate when using anti-phospho-
tyrosine as a primary antibody or anti-rabbit IgG–horsera-
dish peroxidase conjugate when using anti-PKC-y polyclonal
Ab. The membranes were finally washed with washing
solution [50 mM Tris/HCl pH 8.0, 2 mM CaCl2, 80 mM
NaCl, 0.05% (v/v) Tween 20], incubated with enhanced
chemiluminescence detection reagents for 5 min, and ex-
posed to Hyperfilm ECL. The density of bands on the film
was measured using a scanning densitometer (Molecular
Dynamics, Sunnyvale, CA). When reprobing was necessary,
membranes were stripped of bound antibodies by incubation
in stripping buffer (62.5 mM Tris/HCl pH 6.7, 100 mM 2-
mercaptoethanol, 2% (w/v) SDS) at 50 jC for 30 min with
occasional agitation. Membranes were then incubated twice
for 10 min with washing solution and blocked overnight at
4 jC using blotto. Immunodetection was performed as des-
cribed above.
2.2.5. PKC-a kinase activity measurement
Acinar lysates (500 Ag/ml) were inmunoprecipitated with
4 Ag of anti-PKC-a mAb, 4 Ag of rabbit anti-mouse IgG
polyclonal Ab, and 30 Al of protein A–agarose overnight
at 4 jC. Kinase assays were performed using the protein ki-
nase C assay kit from Upstate Biotechnology (Lake Placid,
NY). Immune complexes bound to the protein A–agarose
were washed two times with 1 ml of modified lysis buffer
(50 mM Tris/HCl pH 7.4, 150 mM NaCl, 1% Triton X-100,
1 mM Na3VO4, 5 Ag/ml aprotinin, 5 Ag/ml leupeptin and
1 mM PMSF), and two times with assay dilution buffer
Fig. 3. Effect of CCK-8 and CCK-JMValone or in combination (left panel) and the calcium ionophore A23187 or thapsigargin (TG), alone or in combination
with the phorbol ester TPA (right panel), on PKC-y tyrosine phosphorylation in rat pancreatic acini. Left panel: Acini were incubated with 10 nM CCK-8, with
0.1 AM and 1 AM CCK-JMVor with 10 nM CCK-8 plus 1 AM of CCK-JMV for 2.5 min and then lysed. PKC-y tyrosine phosphorylation was determined by
immunoprecipitation and Western blotting as described in the Fig. 2 legend. The upper part shows results from a representative experiment of three others in
duplicate. The bottom part shows the results of PKC-y tyrosine phosphorylation expressed as the percentage of the maximal increase caused by 10 nM CCK-8.
Values are meanF S.E. of four experiments in duplicate. The asterisk indicates a significant difference as compared to 10 nM CCK-8 alone ( P< 0.01 with
Student’s t-test for unpaired samples). Right panel: Pancreatic acini were treated with the indicated agents for 5 min, and PKC-y tyrosine phosphorylation was
determined as described in the Fig. 2 legend. Results shown in the top panel are from a typical experiment representative of three others in duplicate. Results in
the bottom panel are the meanF S.E. of four experiments expressed as the percentage of the maximal increase of PKC-y tyrosine phosphorylation caused by 0.1
AM TPA above control.
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(20 mM MOPS, pH 7.2, 25 mM h-glycerophosphate, 1 mM
sodium orthovanadate, 1 mM dithiothreitol and 1 mM
CaCl2). Following the last wash, the pelleted beads were
resuspended in 40 Al of assay dilution buffer containing 5 Ag
of phosphatidylserine and 0.5 Ag of diacylglycerol. The
kinase reaction was initiated with the addition of myelin
basic protein (50 Ag) and a magnesium/ATP mixture (75 mM
MgCl2 and 0.5 mM ATP) containing 10 ACi of [g-32P] ATP
(3000 Ci/mmol). The reaction mixtures were briefly mixed
and incubated at room temperature for 15 min with occa-
sional mixing. To stop the kinase reaction, 10 Al of 4 SDS
sample buffer was added and samples were boiled for 5 min.
Sample proteins were resolved using 4–20% SDS-PAGE
gels. Gels were dried and analyzed in a phosphoimager
(InstantImager, Packard Instruments Co., Meriden, CT).
3. Results
3.1. Tyrosine phosphorylation of PKC- in rat pancreatic
acini in response to CCKA receptor activation: kinetics and
dose dependence, and ability of CCK to activate PKC-
After incubating pancreatic acini with 10 nM CCK-8, cell
lysates were subjected to immunoprecipitation with an anti-
PKC-y polyclonal Ab and the immunoprecipitated proteins
were analyzed by Western blotting with anti-phosphotyro-
sine mAb. CCK-8 (Fig. 1, upper panel) caused a marked
increase in the tyrosine phosphorylation of PKC-y (lane 3).
An identical result was obtained when the acini lysates were
first immunoprecipitated with anti-phosphotyrosine mAb
and then analyzed with anti-PKC-y polyclonal Ab (Fig. 1,
bottom panel, lane 3). Following stripping of the membrane
used in Fig. 1, top panel, from anti-phosphotyrosine anti-
bodies, Western blotting with anti-PKC-y polyclonal Ab
showed that the amount of PKC-y from acinar lysates was
not altered by treatment with CCK-8 10 nM (Fig. 1, middle
panel). These results demonstrated that PKC-y is expressed
in rat pancreatic acini and that CCK-8 stimulates its tyrosine
phosphorylation.
Tyrosine-phosphorylated PKC-y in unstimulated samples
was consistently below the level of detection (Fig. 2). How-
ever, tyrosine phosphorylation of PKC-y was a rapid con-
sequence of the addition of 10 nM CCK-8 to pancreatic acini
(Fig. 2, upper panel). An increase of 60F 19% of maximum
stimulation was detected 30 s after addition of CCK-8,
reached a maximum within 5 min and was maintained for
72F 15% of maximum for at least 30 min. The effect of
CCK-8 on PKC-y tyrosine phosphorylation was concentra-
tion-dependent (Fig. 2, lower panel). At a 0.3 nM concen-
tration, CCK-8 caused a 17% increase in PKC-y tyrosine
phosphorylation, a half-maximal effect occurred at 1 nM and
a maximal effect at 100 nM (Fig. 2, lower panel). Reprobing
the same blots with an anti-PKC-y mAb confirmed that an
equivalent amount of PKC-y was inmunoprecipitated at each
point (data not shown). These results demonstrate that
activation of CCKA receptor in rat pancreatic acini causes
rapid tyrosine phosphorylation of PKC-y in a concentration-
dependent manner.
Numerous studies demonstrated that the pancreatic CCKA
receptor exists in at least two binding states [4,5,27,28] and
each state has a different set of secondary messengers and
different biological effects [27,28]. CCK-JMV-180 is repor-
Fig. 4. Calcium dependence of CCK-8 and phorbol ester stimulation of
PKC-y tyrosine phosphorylation in rat pancreatic acini. Pancreatic acini
were pretreated for 30 min at 37 jC in a calcium-free medium (with EGTA
5 mM) either in the absence or presence of BAPTA-AM (50 AM). Acini
were then incubated for a further 2.5 min with CCK-8 (10 nM) (lanes 5 and
6) or for a further 5 min with TPA (1 AM) (lanes 3 and 4) or with no
additions (lanes 1 and 2). PKC-y tyrosine phosphorylation was determined
by immunoprecipitation and Western blotting as described in the Fig. 2
legend. The upper panel, inset, shows the results for a single experiment
representative of at least three others. The bottom panel shows the
meanF S.E. of at least four experiments expressed as the percentage of the
increase of PKC-y tyrosine phosphorylation caused by 10 nM CCK-8
above control. The inset shows the effect of 10 nM CCK-8 on [Ca2 +]i in
pancreatic acini pretreated without or with 50 AM BAPTA-AM for 30 min
in a calcium-free medium.
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ted to be an agonist of the CCKA high affinity receptor state
and an antagonist of the low affinity CCKA receptor state in
rat pancreatic acini [27,28]. Because of this ability to
distinguish between the two affinity states of the CCKA
receptor, we used this peptide to establish which of these
states stimulates PKC-y tyrosine phosphorylation. Incuba-
tion of pancreatic acini with 0.1 or 1 AM CCK-JMV-180
had no effect on PKC-y tyrosine phosphorylation (Fig. 3,
left panel). However, incubation of pancreatic acini with 1
AM CCK-JMV-180 caused an inhibition of CCK-8 stimu-
lation (10 nM) of PKC-y tyrosine phosphorylation by
76F 8% (Fig. 3, left panel). This result supports the con-
clusion that CCK-8 stimulation of PKC-y tyrosine phos-
phorylation is mediated by the low CCKA receptor affinity
state. The fact that the tyrosine phosphorylation of PKC-y
occurs in the CCK-8-concentration range for the occupation
of low affinity state [4] also supports this idea (Fig. 3, lower
panel).
Fig. 6. Time-course (top panel) and concentration dependence (bottom
panel) of the phorbol ester TPA stimulation of PKC-y tyrosine phosphor-
ylation in rat pancreatic acini. Rat pancreatic acini were treated with 1 AM of
TPA for the indicated times (top panel) or were treated for 5 min with the
indicated concentrations of TPA (bottom panel) and then lysed. PKC-y
tyrosine phosphorylation was determined by immunoprecipitation and
Western blotting as described in the Fig. 2 legend. Top panel: The upper part
shows a PKC-y tyrosine phosphorylation result from a representative
experiment with no additions or with 1 AM of TPA at the indicated times.
This result is representative of three others in duplicate. The bottom part of
the top panel shows the quantification of PKC-y tyrosine phosphorylation.
Values are meanF S.E. (n= 4) expressed as the percentage of maximal
increase caused by 1 AM TPA at 5 min above control unstimulated values.
Bottom panel: The upper part shows results from a representative
experiment with TPA at the indicated concentrations. These results are
representative of three others in duplicate. The values shown in the bottom
part of the lower panel are meanF S.E. (n= 4) and are expressed as the
percentage of maximal response caused by 10 AM of TPA above unsti-
mulated values.
Fig. 5. Effect of the PI3-kinase inhibitors wortmannin and LY 294002 on
CCK-8 stimulation of PKC-y tyrosine phosphorylation in rat pancreatic acini.
Pancreatic acini were pretreated for 1 h at 37 jC either in the absence or
presence of 1 AM wortmannin or 100 AM LY 294002. Acini were then
incubated for a further 2.5 min with no additions or with 10 nM CCK-8 and
then lysed. PKC-y tyrosine phosphorylation was determined as described in
the Fig. 2 legend. The upper panel shows results from a typical experiment
representative of three others in duplicate. The bottom panel shows the
meanF S.E. from four experiments and the data are expressed as the per-
centage of the increase in phosphorylation caused by 10 nM CCK-8 above
the control unstimulated values.
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3.2. Effect of intracellular calcium concentration in CCK-8
stimulated PKC- tyrosine phosphorylation
CCKA receptor activation results in the release of Ca
2 +
from intracellular stores followed by the influx of Ca2 + from
the medium [5,10,28,29]. To examine the role of intracellular
calcium in CCK-8-stimulated PKC-y tyrosine phosphoryla-
tion, we used two different approaches. First, we determined
whether an increase on [Ca2 +]i could alter tyrosine kinase
pathways. To assess this we used A23187, a calcium ion-
ophore, and thapsigargin, an agent that specifically inhibits
the endoplasmic reticulum Ca2 +-ATPase [29], depleting
Ca2 + from intracellular compartments and causing an in-
crease in the [Ca2 +]i. Calcium ionophore (1 AM) and thapsi-
gargin (1 AM) under conditions known to increase [Ca2 +]i
[29], did not modify PKC-y tyrosine phosphorylation (Fig. 3,
right panel). In the second approach, we pretreated pancre-
atic acini (1 h in a calcium-free medium containing 5 mM
EGTA) with BAPTA (50 AM) or with thapsigargin (10 AM)
to completely inhibit the subsequent CCK-8 induced [Ca2 +]i
increase. Results with BAPTA are shown in Fig. 4. Neither
BAPTA (Fig. 4, lanes 1, 2) nor thapsigargin significantly
modified the basal tyrosine phosphorylation in control cells
and neither pretreatment with BAPTA nor thapsigargin
inhibited CCK-8 or TPA-stimulated PKC-y tyrosine phos-
phorylation. However, treatment of acini with BAPTA (Fig.
4, lanes 3–6) in a calcium-free medium significantly
increased CCK-8- and TPA-induced PKC-y tyrosine phos-
phorylation by more than 50% over that seen with CCK-8 or
TPA alone. These results demonstrate that increases in
[Ca2 +]i alone do not lead to an increase in PKC-y tyrosine
phosphorylation and that intracellular calcium mobilization
Fig. 7. Effect of the PKC inhibitor GF 109203X on CCK-8 and phorbol ester stimulation of p125FAK, paxillin and PKC-y tyrosine phosphorylation in rat
pancreatic acini. Pancreatic acini were pretreated with 5 AM GF 109203X for 2 h at 37 jC and then incubated for a further 2.5 min with 10 nM CCK-8 or for 5
min with 1 AM TPA or with no additions (control). PKC-y tyrosine phosphorylation was detected as described in Fig. 2 legend. p125FAK and paxillin tyrosine
phosphorylation was determined as described previously [9]. Left panel: The upper part shows results of p125FAK and paxillin tyrosine phosphorylation from a
typical experiment representative of three others. The bottom part of the left panel shows the meanF S.E. of four experiments with results expressed as the
percentage of the maximal increase in phosphorylation caused by 1 AMTPA above the control unstimulated values. Right panel: The upper part shows the results
with PKC-y tyrosine phosphorylation from a typical experiment representative of three others in duplicate. In the bottom part of the right panel are shown the
meanF S.E. from four experiments and the data are expressed as the percentage of the increase in phosphorylation caused by 10 nM CCK-8 over control values.
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is not essential for the ability of CCK-8 to stimulate PKC-y
tyrosine phosphorylation. However, because the magnitude
of CCK-stimulated PKC-y tyrosine phosphorylation was
augmented by inhibiting the CCK-stimulated increase in
[Ca2 +]i, these results suggest that the CCK-stimulated
increases in [Ca2 +]i could be activating an inhibitory process
that was counter-regulating the increase caused by CCK in
PKC-y tyrosine phosphorylation.
3.3. Role of phosphoinositides in CCK-8-stimulated PKC-
tyrosine phosphorylation
As reported previously [5,30], the metabolism of phos-
phoinositides by the different phosphoinositide kinases is a
key event in transmitting signals in response to a variety of
hormones and growth factors including CCK. Because
recent studies suggest PI-3 kinase activity may be important
in PKC-y tyrosine phosphorylation caused by antigen recep-
tor cross-linking in B cells [31], we investigated the effect of
two known PI-3 kinase inhibitors, LY 294002 and wortman-
nin, on CCK-stimulated PKC-y tyrosine phosphorylation.
Treatment of pancreatic acini with LY 294002 (100 AM) or
wortmannin (1 AM) for 1 h had no effect on CCK-8
stimulation of PKC-y tyrosine phosphorylation (Fig. 5, lanes
5 and 6). However, we have previously shown that under the
same experimental conditions, both LY 294002 and wort-
mannin inhibited CCK-8, EGF, and carbachol stimulation of
p125FAK, p130Cas, and paxillin tyrosine phosphorylation in
pancreatic acini [32]. These results demonstrate that PI-3
kinase activation is not essential for the ability of CCK-8 to
stimulate PKC-y tyrosine phosphorylation in rat pancreatic
acini.
3.4. Effect of PKC activation on PKC- tyrosine
phosphorylation
CCKA receptor occupation causes activation of PLC with
the hydrolysis of phosphatidylinositol 4,5-bisphosphate,
which increases production of inositol phosphates and
diacylglycerol, which in turn leads to mobilization of
cellular calcium and activation of PKC isoforms, respec-
tively [5,28]. Previous studies have demonstrated that rat
Fig. 8. Dose– inhibition curve of GF 109203X on CCK-8 and phorbol ester stimulation of PKC-y tyrosine phosphorylation in rat pancreatic acini. Pancreatic
acini were preincubated with the indicated concentrations of GF 109203X for 2 h at 37 jC and then incubated for a further 2.5 min with 10 nM CCK-8, for 5
min with 1 AM TPA, or with no additions. PKC-y tyrosine phosphorylation was determined by immunoprecipitation and Western blotting as described in Fig. 2
legend. The upper panel shows results from a typical experiment representative of four others in duplicate. In the bottom panel are shown the meanF S.E. of
four experiments with results expressed as the percentage of the increase of PKC-y tyrosine phosphorylation caused by 10 AM CCK-8 (right) or 1 AM TPA
(left) above control. Statistical comparisons were performed using Student’s t test for unpaired samples (**P < 0.01; *P< 0.05) compared to TPA or CCK alone.
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pancreatic acini posses both cPKCs and nPKCs [25,26]. To
determine whether activation of cPKC or nPKC isoforms
modify the tyrosine phosphorylation of PKC-y, pancreatic
acini were treated with the phorbol ester, TPA, which
directly activates both cPKC and nPKC [15,33]. Treatment
of pancreatic acini with TPA caused a marked increase in
the tyrosine phosphorylation of PKC-y (Fig. 1, top panel,
lane 2) determined by using immunoprecipitation with an
anti-PKC-y and Western Blotting with anti- phosphotyro-
sine mAb. Identical results were obtained when both anti-
bodies were used in reverse order (Fig 1, bottom panel, lane
2). Western blotting of PKC-y immunoprecipitated with
anti-PKC-y polyclonal Ab showed that the amount of
PKC-y from cell lysates was not altered by treatment with
TPA for 5 min (Fig. 1, middle panel, lanes 1 and 2). Ty-
rosine phosphorylation of PKC-y was a rapid consequence
of the addition of 1 AM TPA to pancreatic acini (Fig. 6,
upper panel). The maximal effect was observed within 5
min, then decreased slowly after 10 min, and remained
46F 3% of maximal response after 30 min. The effect of
TPA on PKC-y tyrosine phosphorylation was concentration-
dependent (Fig. 6, lower panel) with TPA causing a half-
maximal effect at 0.3 AM and a maximal effect at 10 AM
(Fig. 6, lower panel).
With a number of cellular processes in rat pancreatic acini
[4,10,28], simultaneous increases in [Ca2 +]i and PKC acti-
vation have a potentiating effect. To determine whether
similar effects occurring with PKC-y tyrosine phosphoryla-
tion, the calcium ionophore, A23187, or thapsigargin in a
calcium-containing medium were added with TPA (Fig. 3,
right panel). The simultaneous stimulation with both TPA
(0.1 AM) and A23187 (1 AM) or thapsigargin (1 AM) did not
modify the PKC-y tyrosine phosphorylation achieved with
TPA alone (Fig. 3, right panel).
To determine whether PKC activation might be involved
in mediating the CCK-8-stimulated changes in PKC-y tyro-
sine phosphorylation, we examined the effect of the broad
spectrum PKC inhibitor, GF 109203X [34,35]. Pretreatment
of pancreatic acini with GF 109203X (5 AM) alone for 2 h had
no effect on basal PKC-y tyrosine phosphorylation (Fig. 7,
right panel, lanes 1 and 2). However, under these conditions
GF 109203X (5 AM) significantly (P < 0.01) increased CCK-
8 (10 nM) and TPA (1 AM) stimulation of PKC-y tyrosine
phosphorylation to 210F 34% and 203F 32% of control,
respectively (Fig. 7, right panel) over the levels seen with
CCK-8 without pretreatment with GF 109203X. In the same
lysates, GF 109203X pretreatment inhibited completely
TPA-stimulated p125FAK and paxillin tyrosine phosphoryla-
tion (Fig. 7, left panel), as we have previously shown [9].
Previous studies have shown that GF 109203X has a greater
ability to inhibit cPKCs than nPKCs, but can inhibit both at
high concentrations [35,36]. To investigate further this pos-
sibility, we pretreated the pancreatic acinar cells for 2 h with
different concentrations of GF 109203X (1–100 AM) (Fig.
8). Low GF 109203X concentrations (1 and 5 AM) signifi-
cantly increased the tyrosine phosphorylation of PKC-y
Fig. 9. Effect of the cPKC inhibitor Go¨ 6976 on CCK-8 and phorbol ester
stimulation of PKC-y tyrosine phosphorylation in rat pancreatic acini.
Pancreatic acini were pretreated for 2 h at 37 jC either in the absence or
presence of 10 AM Go¨ 6976 and then incubated for a further 2.5 min with
CCK-8 (10 nM) or 5 min with TPA (1 AM). PKC-y tyrosine phosphorylation
was detected as described in Fig. 2 legend. The top panel shows results from
a typical experiment representative of three others performed in duplicate.
The bottom panel shows the quantification of PKC-y tyrosine phosphor-
ylation. Values are meanF S.E. (n= 4) expressed as the percentage of the
increase caused by 10 nM CCK-8 above control unstimulated values.
( P< 0.01 with Student’s t-test for unpaired samples).
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stimulated by TPA or CCK-8 (Fig. 8, lanes 2–4 and 7–9).
Pretreatment with high concentrations of GF 109203X (30
and 100 AM) reduced the tyrosine phosphorylation of PKC-y
stimulated by CCK-8 or TPA by >50% (Fig. 8). These results
suggest that at lower concentrations, GF 109203X reduces
the effect of activation of an inhibitory factor, perhaps a
conventional PKC, and at higher concentrations, inhibits all
PKCs as seen in other cell systems [35,36].
To study further the role of activation of possible PKCs
in mediating CCK-8-stimulated increases in PKC-y tyrosine
phosphorylation, we used Go¨ 6976 and safingol, which in
other cell systems are more selective cPKC inhibitors [35–
39]. Pretreatment of pancreatic acini with Go¨ 6976 (10 AM)
alone for 2 h had no effect on basal PKC-y tyrosine
phosphorylation (Fig. 9, lane 2). However, Go¨ 6976 in-
creased significantly (P < 0.01) by 182F 49% and 204F
46% the PKC-y tyrosine phosphorylation stimulated by
CCK-8 (10 nM) and TPA (1 AM), respectively (Fig. 9).
Treatment with safingol (10 AM) for 2 h increased signifi-
cantly (P < 0.01) by 75F 23% and 180F 77% the PKC-y
tyrosine phosphorylation stimulated by CCK-8 (10 nM) and
TPA (1 AM), respectively (Fig. 10, lower panel). Under the
same conditions, safingol alone had no effect on basal
PKC-y tyrosine phosphorylation (Fig. 10, lower panel, lane
2) or basal PKC-a kinase activity (Fig. 10, lane 3) but
markedly inhibited the TPA-stimulated PKC-a kinase activ-
ity (Fig. 10, upper panel, lanes 2 and 4). The results with
TPA and PKC inhibitors demonstrate that activation of dif-
ferent PKC isoforms in pancreatic acini have both stimula-
tory and inhibitory effects on the tyrosine phosphorylation
of PKC-y.
4. Discussion
Numerous stimulants cause tyrosine phosphorylation of
the nPKC isoform, PKC-y, including growth factors [14,16,
19,23,40], oxidative stress [41], Ras [19], and activation of a
few G protein-coupled receptors (angiotensin II, substance P,
muscarinic cholinergic, ATP, a-adrenergic) [16,42,43]. A
number of results support the conclusion that stimulation
of the CCKA-R in rat pancreatic acini results in PKC-y
tyrosine phosphorylation, which is mediated through activa-
tion of its low affinity state. First, whether immunoprecipi-
tation was performed with an anti-PKC-y antibody and
Western blotting performed with an anti-phosphotyrosine
mAb or the same antibodies used in reverse order, CCK
stimulated phosphorylation of a single immunoreactive
band. Second, the dose–response curve for PKC-y tyrosine
phosphorylation occurred over the concentration range that
CCK-8 stimulates activation of its low affinity receptor state
[4,27]. Numerous binding studies demonstrate the pancreatic
CCKA-R exists in high- and low-affinity states [4,27,44]. and
activation of the two states are associated with stimulation of
different secondary messengers and biologic responses
[44,45]. The CCK-8 analogue, CCK-JMV-180, is an agonist
Fig. 10. Effect of the cPKC inhibitor safingol on TPA-stimulated PKC-a
kinase activity and on CCK-8 and TPA stimulation of PKC-y tyrosine
phosphorylation in rat pancreatic acini. Top panel: Acinar lysates were
incubated with TPA (1 AM) for 5 min in the absence or presence of 10 AM
of safingol. PKC-a kinase activity was measured as described in Methods.
The figure shows results from a typical experiment representative of three
others. Bottom panel: Pancreatic acini were pretreated for 2 h at 37 jC
either in the absence or presence of 10 AM safingol and then incubated for a
further 2.5 min with CCK-8 (10 nM) or 5 min with TPA (1 AM). PKC-y
tyrosine phosphorylation was detected as described in Fig. 2 legend. The
upper part of the bottom panel shows results from a typical experiment
representative of three others performed in duplicate. The lower part of the
bottom panel shows the quantification of PKC-y tyrosine phosphorylation.
Values are meanF S.E. (n= 4) expressed as the percentage of the increase
caused by 10 nM CCK-8 above control unstimulated values.
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at the CCKA high affinity and an antagonist at the low
affinity receptor state in rat pancreatic acini [27]. CCK-JMV-
180 did not stimulate tyrosine phosphorylation of PKC-y,
suggesting that CCK-8’s ability to stimulate PKC-y tyrosine
phosphorylation is due to activation of the low affinity
CCKA-R state. This conclusion was confirmed by demon-
strating that CCK-JMV-180 inhibited CCK-8’s ability to
stimulate PKC-y tyrosine phosphorylation due to its ability
to act as a receptor antagonist of this state [27].
CCK’s stimulation of PKC-y tyrosine phosphorylation
has similarities and differences from both the ability of other
stimulants in other cells to cause PKC-y tyrosine phosphor-
ylation and the ability of CCKA-R activation to cause
tyrosine phosphorylation of other proteins in rat pancreatic
acini. The time course of CCK stimulation of PKC-y tyrosine
phosphorylation reached a maximum, then decreased, sug-
gesting that a tyrosine phosphatase was likely also activated.
This time course is similar to that seen with insulin stim-
ulation of PKC-y tyrosine phosphorylation in rat skeletal
muscle [23], but differs from that caused by carbachol or
substance P in salivary epithelial cells in which the initial
increase in tyrosine phosphorylation completely disappeared
within 15 min [16], or thrombin in platelets in which a
biphasic temporal pattern of PKC-y phosphorylation was
seen [46]. At present, the significance of the variable
temporal patterns of PKC-y tyrosine phosphorylation in
different cells with different stimuli is unknown. CCKA-R
activation in rat pancreatic acini has been shown to cause
tyrosine phosphorylation of p125FAK [9], paxillin [9],
p130Cas [11], PYK2/CAKh [10], Jun kinase [5,47], MAP
kinase [5,48], and PI-3 kinase [49]. In contrast to PKC-y
tyrosine phosphorylation, which is mediated only by activa-
tion of the low affinity state of the CCKA-R, stimulation of
tyrosine phosphorylation of p125FAK, paxillin, and PYK2/
CAKh [10] in rat pancreatic acini by CCK was stimulated by
activation of both the high and low CCKA-R states. These
results demonstrate that not only are the phospholipase A2
and PLC cascades coupled differently to high and low
affinity CCKA-R states as described previously [44], but
also the tyrosine phosphorylation cascades activated by
CCKA-R are differentially coupled to these two different
receptor states.
Activation of the CCKA-R causes stimulation of PLC
activity [4,5]. Even though PKC-y is a calcium-independent,
DAG-dependent kinase [14,15] and the role of DAG in
stimulating its kinase activity has been well studied
[14,15,33], much less is known about the participation of
the PLC cascade in mediating PKC-y tyrosine phosphoryla-
tion from studies in different cells by various stimuli.
Inhibition of PLC activation simulated by substance P or
carbachol in salivary epithelial cells [18], or in B cells due to
activation of the B cell antigen receptor [50], resulted in
inhibition of PKC-y tyrosine phosphorylation caused by
these stimuli, demonstrating that activation of the PLC
cascades is needed to stimulate PKC-y tyrosine phosphor-
ylation in these cells. However, increasing [Ca2 +]i in salivary
epithelial cells by a calcium ionophore [16,18] did not sti-
mulate tyrosine phosphorylation of PKC-y, or inhibition of
[Ca2 +]i increases caused by substance P or carbachol in
salivary epithelial cells [18] did not inhibit their ability to
cause PKC-y tyrosine phosphorylation, suggesting that
changes in [Ca2 +]i alone were not sufficient to stimulate or
inhibit stimulated PKC-y tyrosine phosphorylation in these
cells. In contrast to the lack of effect changes in [Ca2 +]i, the
phorbol ester, TPA, which can activate all cPKC and nPKC
isoforms [15,33], stimulated PKC-y tyrosine phosphoryla-
tion in salivary epithelial cells [16] and in 32D hematopoietic
cell line [51]. Whereas these results would suggest that in
these tissues PKC activation due to DAG generation is
particularly important in regulating the tyrosine kinase(s)
responsible for PKC-y tyrosine phosphorylation, results in
other cells suggest that cell-specific differences exist. For
example, in B cells [50] where activation of the B cell
antigen receptor causes PKC-y tyrosine phosphorylation in
a PLC-dependent manner, TPA does not cause tyrosine
phosphorylation, suggesting that activation of DAG-stimu-
lated pathways alone is not sufficient to stimulate PKC-y
tyrosine phosphorylation in this cell. In our study a number
of results support the conclusion that both CCK-stimulated
increases in DAG and changes in pancreatic acinar [Ca2 +]i
are likely important in determining the maximal extent of
PKC-y phosphorylation stimulated by CCKA-R activation;
however, activation of these two cascades have different
effects (Fig. 11). First, neither increasing [Ca2 +]i using the
calcium ionophore, A23187, nor using the Ca2 +-ATPase
inhibitor, thapsigargin [29], resulted in an increase in PKC-y
tyrosine phosphorylation. Second, inhibition of the increases
in [Ca2 +]i caused by CCKA-R activation using either
BAPTA or thapsigargin did not inhibit CCK-stimulated
increases in PKC-y tyrosine phosphorylation. The lack of
effect of changes in [Ca2 +]i either alone or in combination
with TPA supports the conclusion that increases in [Ca2 +]i
caused by a CCKA-R-stimulated increase in PLC activity in
pancreatic acini are not essential for CCKA-R activation to
stimulate PKC-y tyrosine phosphorylation. These results are
similar to that reported with stimulation of PKC-y tyrosine
phosphorylation in salivary epithelial cells by substance P or
carbachol [16,18] and B cell receptor activation in B cells
[50]. Third, the phorbol ester, TPA, which can mimic the
effects of endogenous increases in DAG in both activating
PKCs and causing PKC translocation to the plasma mem-
brane [14,15,28,33], stimulated PKC-y tyrosine phosphor-
ylation to the same extent seen with CCKA-R activation.
These results suggest that increases in DAG due to CCKA-R
activation in pancreatic acini are likely the principal mech-
anism leading to CCK stimulation of PKC-y tyrosine phos-
phorylation.
In previous studies, CCKA-R activation stimulates both
PLC and phospholipase D (PLD), leading to generation of
DAG [25,28,45]. A number of results support the conclu-
sion that the generation of DAG from PLC activation by
CCK is the important cascade mediating the increase in
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PKC-y tyrosine phosphorylation seen with CCKA-R activa-
tion. First, CCKA-R-mediated PLD stimulation is mediated
by activation of the high affinity CCKA-R state [27,45],
whereas we show that CCK-mediated PKC-y tyrosine
phosphorylation is due to activation of the low affinity state
only, whose activation has been shown to be coupled to
PLC stimulation [27,52]. Second, CCK-JMV, which only
activates the high affinity state [4] and has been shown to
activate PLD [25,27,45], but not PLC [25,27,45,52], did not
stimulate an increase in PKC-y tyrosine phosphorylation.
Third, a previous study [25] has shown that CCK-mediated
PKC-y translocation in pancreatic acini is mediated only by
DAG generated by PLC activation, not from PLD activa-
tion.
In some cells, stimulation of PKC-y tyrosine phosphor-
ylation requires activation of PI-3 kinase [31]. CCKA-R acti-
vation in pancreatic acini has been shown to activate PI-3
kinase [45] and it is proposed this activation is involved in
mediating CCK’s stimulation of tyrosine phosphorylation of
p125FAK, p130Cas, and paxillin [11,32]. In the present study
we provide evidence that PI-3 kinase activation is not re-
quired for stimulation of PKC-y tyrosine phosphorylation,
using two different inhibitors of PI-3 kinase: wortmannin,
which inhibits PI-3 kinase catalytic activity, and LY 294002,
which inhibits by acting at the ATP binding site of the PI-3
kinase [30]. These results are similar to the lack of involve-
ment of PI-3 kinase in TPA- or carbachol-stimulation of
PKC-y tyrosine phosphorylation in salivary epithelial cells
[16]; however, they differ from results of B cell antigen re-
ceptor stimulation of PKC-y tyrosine phosphorylation, which
is dependent on PI-3 kinase activation [31].
The role of activation of PKCs in stimulation of the
tyrosine kinase(s) that cause PKC-y tyrosine phosphoryla-
tion is unknown. In the present study, to provide insight into
this area we investigated the effect of incubations in
calcium-free conditions inhibiting activation of cPKCs and
of several PKC inhibitors with different PKC isoform
selectivities. CCK or TPA in calcium-free conditions caused
an increase in PKC-y tyrosine phosphorylation, suggesting
activation of cPKCs could be having an inhibitory effect. To
provide additional support for this conclusion, the effects of
GF 109203X, a broad-range PKC inhibitor with greater
ability to inhibit cPKCs but which also can inhibit nPKCs
[34–36], and Go¨ 6976 and safingol, which are more specific
inhibitors for cPKCs [35–39], were determined. Previous
studies show that rat pancreatic acinar cells possess only one
cPKC (PKC-a), two nPKCs (PKC-y and PKC-q), and the
atypical PKC, PKC-~ [25,26]. A number of our results
support the conclusion that activation of at least the PKC
isoform, PKC-a, and maybe others, is involved in regulat-
ing CCKA-R stimulation of tyrosine kinases or tyrosine
phosphatases that alter the tyrosine phosphorylation of
PKC-y. First, GF 109203X had a biphasic effect on CCK-
stimulated PKC-y tyrosine phosphorylation. The augmenta-
tion of the ability of CCK to stimulate PKC-y tyrosine
phosphorylation when GF 109203X was added at low
concentrations is consistent with the suggestion that inhib-
ition of a cPKC is having an inhibitory effect. The inhibitory
effect of GF 109203X at higher concentrations is compat-
ible with its ability to inhibit all nPKC and cPKCs, includ-
ing PKC-y, at these concentrations. Second, studies using
the structurally unrelated cPKC-selective antagonists, Go¨
6976 and safingol [35–37,39], suggest that inhibition of a
cPKC was in fact responsible for the increase in CCK-
stimulated PKC-y tyrosine phosphorylation seen with GF
109203X.
On the basis of the results in this study, the model shown
in Fig. 11 can be proposed for the ability of CCKA-R acti-
vation in pancreatic acinar cells to cause PKC-y tyrosine
phosphorylation. CCKA-R activation of PLC resulting in
increases in [Ca2 +]i from intracellular sources [5] is not
essential for CCK to cause stimulation of PKC-y tyrosine
phosphorylation. However, CCKA-R-activation-stimulated
increases in [Ca2 +]i, in combination with increases in
DAG, activate PKC-a, which has an inhibitory effect on
CCK-stimulated PKC-y tyrosine phosphorylation. The
Fig. 11. Proposed model of CCKA receptor-mediated PKC-y tyrosine
phosphorylation in rat pancreatic acini. Stimulation of CCKA receptor leads
to phospholipase C activation, which results in increases in intracellular
calcium and diacylglycerol (DAG) concentrations. Increases in DAG or
TPA treatment promote the tyrosine phosphorylation of PKC-y by
activation of an unknown tyrosine kinase. This could be mediated either
through activation of an nPKC or possibly by translocation of PKC-y to the
plasma membrane where tyrosine phosphorylation occurs, possibly due to
Src activation. At the same time, activation of the conventional PKC
isoform, PKC-a, inhibits PKC-y tyrosine phosphorylation. PKC-a-
mediated inhibition could occur by inhibition of the tyrosine kinase
involved in PKC-y tyrosine phosphorylation or by activation of a tyrosine
phosphatase.
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inhibitory effect of PKC-a could be due to either inhibition
of tyrosine kinase(s) or activation of tyrosine phospha-
tase(s). We have no direct evidence to favor either of these
two possibilities. However, CCKA-R activation in rat pan-
creatic acini has been shown to increase protein tyrosine
phosphatase activity [45]. Furthermore, with CCK-stimu-
lated PKC-y tyrosine phosphorylation in the present study
as well as in others [9–11], there was a fall-off in the
magnitude of maximal stimulation with time, suggesting
that tyrosine phosphatases are also stimulated by CCKA-R
activation [9–11]. CCKA-R activation in pancreatic acini
causes an increase in DAG from activation of phospholi-
pases [25] and our results are consistent with the conclusion
that this increase alone from PLC activation without
changes in [Ca2 +]i can activate the tyrosine kinase cascade
causing PKC-y tyrosine phosphorylation. The evidence for
this is that TPA, which can mimic the actions of endogenous
DAG, alone stimulates PKC tyrosine phosphorylation in
pancreatic acini. Also supporting this conclusion is the
result that CCK-JMV, which activates phospholipase D
and not PLC [25,27,45,52], failed to stimulate PKC-y
tyrosine phosphorylation. The mechanism by which TPA
or CCK activates the tyrosine kinase that phosphorylates
PKC-y, as indicated in Fig. 11, is by activation of an nPKC,
which then activates the tyrosine kinases. We have no direct
evidence to support this in the present study. However, the
ability of high concentrations of GF 109203X to inhibit
either TPA- or CCK-stimulated tyrosine phosphorylation
raises this possibility, because at these concentrations it
inhibits all of the cPKCs and nPKCs which are found in
pancreatic acini [25,26]. This possibility is indicated on the
diagram in Fig. 11 by a query because of lack of direct
evidence to support it and also because some evidence
supports a second possibility. Recently it was proposed in
B cells that TPA or DAG causes PKC-y to translocate to the
plasma membrane, where a tyrosine kinase, perhaps a
member of the Src family, can phosphorylate it [50]. In a
number of different cells, Src family members promote
PKC-y tyrosine phosphorylation [14,17,18,21] and previous
studies demonstrate that both TPA treatment and CCKA-R
activation in rat pancreatic acinar cells cause translocation of
PKC-y to the plasma membrane [25] as well as activation of
Src [53]. The possibility of this pathway occurring in rat
pancreatic acini is further supported by the demonstration
that the CCKA-R activation in these cells activates Src
through its low affinity receptor state, which is the same
receptor state we demonstrate in this study as responsible for
mediating CCK-stimulated increases in PKC-y tyrosine
phosphorylation. A recent study [21] demonstrates that
Src-promoted PKC-y tyrosine phosphorylation leads to
increased PKC-y degradation and this decreases the amount
of PKC-y in the cell. Further experiments are required to
establish if CCK mediates a similar effect in rat pancreatic
acini. However, if CCK activates this mechanism in acini,
the simultaneous activation of PKC-a by CCK, which
inhibits the amount of PKC-y tyrosine phosphorylation,
presumably could inhibit the degradation of PKC-y after a
prolonged time period resulting in stabilization of its
amount in the cell. This pathway could be the second
counter-regulatory mechanism involving PKC-a that regu-
lates the amount of PKC-y abundance. Recently [54],
increased expression of PKC-a mRNA has been shown to
increase the abundance of PKC-y mRNA and PKC-y
protein, demonstrating that PKC-a is uniquely involved in
cross-regulating PKC-y abundance.
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